T1	p 92 112	stable COPD patients
T2	p 129 142	COPD patients
T3	p 596 612	60 COPD patients
T4	i 718 725	placebo
T5	i 735 746	indacaterol
T6	o 462 506	specific airway resistance changes ( ?sRAW )
T7	o 623 655	dyspnea evaluation ( VAS score )
T8	o 660 678	pulmonary function
T9	o 772 809	Spirographic and ?sRAW-based criteria
T10	o 904 938	intrathoracic gas volume ( ?ITGV )
T11	o 964 987	residual volume ( ?RV )
T12	o 1013 1017	?FVC
T13	o 1081 1086	?FEV1
T14	o 1108 1112	?FVC
T15	o 1172 1177	?ITGV
T16	o 1192 1195	?RV
T17	o 1214 1218	?VAS
T18	o 1288 1293	?sRAW
T19	o 1488 1503	improvements of